GUJARAT THEMIS BIOSYN LTD.

Gujarat Themis Biosyn Ltd announced key resolutions passed by its members, including the approval of a dividend of ₹0.67 per equity share (67%) for the Financial Year ended March 31, 2026, amounting to ₹8,72,01,642. The company also received approval for raising funds through a preferential issue and amendments to its Articles of Association. The AOA amendment specifically allows financial institutions to appoint observers on the Board under certain conditions related to outstanding liabilities or debentures.

Gujarat Themis Biosyn Ltd has announced the closure of its trading window from October 1, 2026, until after the declaration of its un-audited financial results for the quarter and half-year ending September 30, 2026. The specific date for the Board Meeting to consider these results will be communicated later. This measure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, to prevent potential insider trading during the period leading up to the financial results announcement.

Gujarat Themis Biosyn Limited has issued a corrigendum to its 45th Annual General Meeting (AGM) notice, amending Resolution No. 8 and its explanatory statement. The amendments pertain to a preferential issue of equity shares aimed at raising funds. The total issue size has been revised to ₹335,00,00,724, with up to 82,92,081 equity shares to be issued at ₹404 per share. The funds will be utilized for redemption of NCDs/repayment of borrowings for acquisition of MicroBiopharm Japan Co., Ltd. and for general corporate purposes. India Rating and Research Private Limited has been appointed as the monitoring agency for fund utilization.

Gujarat Themis Biosyn Ltd has announced that the Board of Directors has fixed Wednesday, September 23, 2026, as the record date. This date is for determining shareholders' entitlement to receive a dividend for the financial year ended March 31, 2026. The dividend is subject to approval by the members at the upcoming 56th Annual General Meeting, scheduled for Wednesday, September 30, 2026. The company has informed the stock exchange as per SEBI Listing Regulations.

Gujarat Themis Biosyn Limited (GTBL) has successfully acquired 100% equity in MicroBiopharm Japan Co., Ltd. (MBJ) through its subsidiary, Themis Biosyn Japan Limited. The acquisition, valued at JPY 21.5 billion, was funded by a mix of debt and equity, with GTBL investing INR 475 Crores in capital and INR 745 Crores via loan to its subsidiary. MBJ, with over 60 years of experience, operates three GMP-compliant manufacturing plants and reported FY26 revenue of JPY 9.5 billion. This strategic move is expected to enhance GTBL's fermentation capabilities, product portfolio, and global footprint, positioning it as a fermentation-based, globally integrated CDMO. The acquisition is anticipated to be EPS accretive for GTBL.

Gujarat Themis Biosyn Limited has announced the allotment of Non-Convertible Debentures (NCDs) aggregating ₹585 Crores on a private placement basis. The funds raised will be utilized for investing in its wholly-owned subsidiary in Japan to finance the acquisition of MicroBiopharm Japan Co., Ltd, and for general corporate purposes. The NCDs are secured, redeemable, unlisted, and rated. Two series of NCDs were allotted: Series 1 (₹2,950 million) with a tenure of 60 months and a 10% p.a. interest rate, and Series 2 (₹2,900 million) with a tenure of 18 months and a 17.75% p.a. interest rate. The issuance is secured by company assets and a personal guarantee from the promoter.

Gujarat Themis Biosyn Ltd announced that its Board of Directors, in a meeting held on September 10, 2026, approved the issuance of Non-Convertible Debentures (NCDs) aggregating up to INR 585 Crores. The issuance will be conducted on a private placement basis. Further details regarding the allotment, tenure, coupon, and security will be disclosed in due course. The board meeting commenced at 5:45 PM and concluded at 7:10 PM.

Gujarat Themis Biosyn Ltd has issued an addendum to its 45th Annual General Meeting (AGM) notice, scheduled for September 30, 2026. The addendum proposes a special resolution to amend Article 119 of the company's Articles of Association. This amendment aims to broaden the definition of 'Financial Institution' and grant them rights to appoint observers on the Board under specific conditions, reflecting evolving financing frameworks. The original notice was dated September 2, 2026.

Gujarat Themis Biosyn Ltd has announced that its Board of Directors will convene on September 10, 2026. The primary agenda item is to consider and approve a proposal for raising funds through the issuance of Non-Convertible Debentures (NCDs) via private placement. Concurrently, the company has closed its trading window for designated persons and their relatives, in compliance with SEBI's insider trading regulations, until further notice.

Gujarat Themis Biosyn Limited reported its financial results for the fiscal year ended March 31, 2026. The company achieved a total income of ₹168.25 crores, with an EBITDA of ₹75.53 crores and a Profit After Tax (PAT) of ₹46.68 crores. Key developments during the year included a significant expansion of fermentation capacity, operationalization of a new API facility, and advancements in R&D. The company also announced strategic inorganic growth initiatives, including the acquisition of 13 global brands from Sanofi and the incorporation of a wholly-owned subsidiary in Japan, Themis Biosyn Japan Limited, along with the acquisition of MicroBiopharm Japan Co. Ltd. These moves aim to strengthen its market position, expand its product portfolio, and increase its global presence.